Comparative Pharmacology
Head-to-head clinical analysis: MONODOX versus SUMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONODOX versus SUMYCIN.
MONODOX vs SUMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Tetracycline antibiotic inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
100 mg orally or IV every 12 hours on day 1, then 100 mg orally or IV every 24 hours; for severe infections, 100 mg every 12 hours.
250-500 mg orally every 6 hours or 500 mg orally every 12 hours (maximum 2 g/day)
None Documented
None Documented
Terminal elimination half-life: 14-22 hours (mean ~18 hours) in adults; prolonged up to 24-48 hours in renal impairment; no dose adjustment in mild-moderate renal impairment but caution in severe (CrCl <30 mL/min).
6-12 hours; prolonged in renal impairment (up to 24-48 hours in anuria)
Renal: ~40% (glomerular filtration, tubular secretion); biliary: ~20-60% (enterohepatic circulation); fecal: ~30% (unabsorbed or excreted in bile).
Renal (60-80% unchanged via glomerular filtration), biliary/fecal (20-40%)
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic